OnKure Therapeutics
OKUR
35 hedge funds and large institutions have $102M invested in OnKure Therapeutics in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 3 closing their positions.
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
166% more capital invested
Capital invested by funds: $38.4M → $102M (+$63.7M)
13% more funds holding
Funds holding: 31 → 35 (+4)
0.93% more ownership
Funds ownership: 67.12% → 68.05% (+0.93%)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carlyle Group
Washington,
District of Columbia
|
+$7.52M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$1.52M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$438K |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
+$388K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$117K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$163K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$80.4K |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$71.3K |
| 4 |
E
Ergoteles
New York
|
-$70.5K |
| 5 |
Renaissance Technologies
New York
|
-$42K |
OKUR Hedge Fund Activity: Q1 2023 in Review
35 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q1 2023, worth a combined $102M — up 166% from $38.4M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new OKUR positions and 3 closed out — a net gain of 5 holders — while 7 added to existing stakes and 7 trimmed.
The largest buyer was Carlyle Group, opening a new position worth an estimated $7.52M. The largest seller was Bridgeway Capital Management, cutting an estimated $163K.
- 35 institutional investors held OnKure Therapeutics (OKUR) as of Q1 2023, up from 31 in Q4 2022.
- Funds reported $102M of OnKure Therapeutics stock for Q1 2023, up 166% quarter-over-quarter.
- 8 funds opened new OnKure Therapeutics positions in Q1 2023 and 3 closed out, a net change of +5 holders.
- The largest OnKure Therapeutics buyer in Q1 2023 was Carlyle Group, an estimated $7.52M added.
- The largest OnKure Therapeutics seller in Q1 2023 was Bridgeway Capital Management, an estimated $163K sold.
Based on aggregated 13F filings for Q1 2023.